中医药调节肠道菌群及其代谢产物在肝癌发生发展中的免疫机制研究进展

肝癌电子杂志 ›› 2022, Vol. 9 ›› Issue (1): 61-64.

中医药调节肠道菌群及其代谢产物在肝癌发生发展中的免疫机制研究进展

李存雅¹, 付淑娟², 李芸², 钟治贤³, 王治英⁴, 钟薏^2,*

1.上海中医药大学,上海 201203;
2.上海中医药大学附属上海市中西医结合医院肿瘤科,上海 200082;
3.昆明医科大学附属第二临床医学院,云南昆明 650500;
4.天津中医药大学中医学院,天津 301617

收稿日期:2021-10-24 出版日期:2022-03-31 发布日期:2022-10-28
通讯作者: ^*钟薏, E-mail：zhongzixian2000@163.com
作者简介:李存雅, 硕士研究生, 上海中医药大学附属上海市中西, 医结合医院, 肿瘤科
基金资助:
2019年上海市科委科技支撑项目临床医学领域专项（19401971600）; 上海市虹口区医学科研课题青年项目（虹卫1903-01）; 上海市抗癌协会青年医生“雏鹰”计划（SACA-CY19C18）; 上海市中西医结合医院科研课题（中西医18-01-01）

Progress on immune mechanism of traditional Chinese medicine regulating gut microbiota and its metabolites in the occurrence and development of liver cancer

Li Cunya¹, Fu Shujuan², Li Yun², Zhong Zhixian³, Wang Zhiying⁴, Zhong Yi^2,*

1. Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China;
2. Department of Oncology, Shanghai Integrated Traditional Chinese and Western Medicine Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200082, China;
3. Second Clinical Medical College Affiliated to Kunming Medical University, Kunming 650500, Yunnan, China;
4. College of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China

Received:2021-10-24 Online:2022-03-31 Published:2022-10-28

摘要/Abstract

摘要： 中医药在肿瘤临床治疗中发挥着不可或缺的作用,尤其在综合辅助治疗时,可以显著减轻放射治疗、化学药物治疗、靶向治疗、免疫治疗等产生的不良反应,集治、养于一体,扶正祛邪;同时调控肠道菌群及其代谢产物,增加有益菌,减少有害菌,修复肠道微环境,以及调节胆汁酸代谢和免疫因子表达,发挥免疫应答,进而改善肝再生微环境以抑制肝癌的发生发展进程。本文将对中医药调节肠道菌群及其代谢产物在肝癌发生发展中的免疫机制的研究进展进行综述。

关键词: 肝癌, 中医药, 肠道菌群, 胆汁酸, 免疫机制

Abstract: Traditional Chinese Medicine plays an indispensable role in the clinical treatment of tumor, especially in comprehensive adjuvant therapy, it can significantly reduce the adverse reactions caused by radiotherapy, chemotherapy, targeted therapy and immunotherapy, collection of treatment and health in one and strengthening healthy to eliminate pathogens. At the same time, the intestinal microflora and its metabolites are regulated to increase beneficial bacteria and reduce harmful bacteria, repair the intestinal microenvironment, regulate bile acid (BA) metabolism and immune factor expression, exert immune response, and then improve the liver regeneration microenvironment to inhibit the occurrence and development of liver cancer. This review will start with the regulation of intestinal flora by traditional Chinese medicine and explain its immune mechanism in liver cancer.

Key words: Liver cancer, Traditional Chinese Medicine, Gut microbiota, Bile acid, Immune mechanism

李存雅, 付淑娟, 李芸, 钟治贤, 王治英, 钟薏. 中医药调节肠道菌群及其代谢产物在肝癌发生发展中的免疫机制研究进展[J]. 肝癌电子杂志, 2022, 9(1): 61-64.

Li Cunya, Fu Shujuan, Li Yun, Zhong Zhixian, Wang Zhiying, Zhong Yi. Progress on immune mechanism of traditional Chinese medicine regulating gut microbiota and its metabolites in the occurrence and development of liver cancer[J]. Electronic Journal of Liver Tumor, 2022, 9(1): 61-64.

参考文献

[1] ARNOLD M, ABNET C C, NEALE R E, et al.Global Burden of 5 Major Types of Gastrointestinal Cancer[J]. Gastroenterology, 2020, 159(1): 335-349.
[2] OGUNWOBI O O, HARRICHARRAN T, HUAMAN J, et al.Mechanisms of hepatocellular carcinoma progression[J]. World J Gastroenterol, 2019, 25(19): 2279-2293.
[3] 中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会(CSCO)原发性肝癌诊疗指南 2020 [M].北京:人民卫生出版社,2020.
[4] LIU C, WU H, MAO Y, et al.Exosomal microRNAs in hepatocellular carcinoma[J]. Cancer Cell Int, 2021, 21(1): 254.
[5] 金亮亮. 中医药治疗肿瘤化疗后不良反应临床分析[J/CD]. 中西医结合心血管病电子杂志, 2019, 7(34): 172, 181.
[6] 陈燕妮, 王兰兰, 查青, 等. 中医药在肿瘤免疫治疗方面的研究进展[J]. 辽宁中医杂志, 2020, 47(4): 201-203.
[7] 牛璐, 王跃飞, 赵鑫, 等. 中药调控肠道菌群代谢产物的研究进展[J]. 天津中医药, 2021, 38(2): 254-260.
[8] GADALETA R M, SCIALPI N, PERES C, et al.Suppression of Hepatic Bile Acid Synthesis by a non-tumorigenic FGF19 analogue Protects Mice from Fibrosis and Hepatocarcinogenesis[J]. Sci Rep, 2018, 8(1): 17210.
[9] WINSTON J A, THERIOT C M.Diversification of host bile acids by members of the gut microbiota[J]. Gut Microbes, 2020, 11(2): 158-171.
[10] DONIA M S, FISCHBACH M A. HUMAN MICROBIOTA.Small molecules from the human microbiota[J]. Science, 2015, 349(6246): 1254766.
[11] CAFFARATTI C, PLAZY C, MERY G, et al.What We Know So Far about the Metabolite-Mediated Microbiota-Intestinal Immunity Dialogue and How to Hear the Sound of This Crosstalk[J]. Metabolites, 2021,11(6): 406.
[12] RUAN W, ENGEVIK M A, SPINLER J K, et al.Healthy Human Gastrointestinal Microbiome: Composition and Function After a Decade of Exploration[J]. Dig Dis Sci, 2020, 65(3): 695-705.
[13] ZHOU B, YUAN Y, ZHANG S, et al.Intestinal Flora and Disease Mutually Shape the Regional Immune System in the Intestinal Tract[J]. Front Immunol, 2020, 11: 575.
[14] CIANCI R, FRANZA L, SCHINZARI G, et al.The Interplay between Immunity and Microbiota at Intestinal Immunological Niche: The Case of Cancer[J]. Int J Mol Sci, 2019, 20(3): 501.
[15] PAGLIARI D, SAVIANO A, NEWTON E E, et al.Gut Microbiota-Immune System Crosstalk and Pancreatic Disorders[J]. Mediators Inflamm, 2018: 7946431.
[16] TANG J, XU L, ZENG Y, et al.Effect of gut microbiota on LPS-induced acute lung injury by regulating the TLR4/NF-κB signaling pathway[J]. Int Immunopharmacol, 2021, 91: 107272.
[17] GOYAL D, ALI S A, SINGH R K.Emerging role of gut microbiota in modulation of neuroinflammation and neurodegeneration with emphasis on Alzheimer's disease[J]. Prog Neuropsychopharmacol Biol Psychiatry, 2021, 106: 110112.
[18] PI H, HUANG L, LIU H, et al.Effects of PD-1/PD-L1 signaling pathway on intestinal flora in patients with colorectal cancer[J]. Cancer Biomark, 2020, 28(4): 529-535.
[19] NIE D, WANG P, ZANG C, et al. The intestinal flora of patients with GHPA affects the growth and the expression of PD-L1 of tumor[J]. Cancer Immunol Immunother, 2021. Online ahead of print.
[20] WIEST R, ALBILLOS A, TRAUNER M, et al.Targeting the gut-liver axis in liver disease[J]. J Hepatol, 2017, 67(5): 1084-1103.
[21] 王雅欢, 黄晓桃, 吴云霞. 原发性肝癌的发生机制及中西医治疗研究进展[J]. 中西医结合研究, 2019, 11(3): 151-155.
[22] MA C, HAN M, HEINRICH B, et al. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells[J]. Science, 2018, 360(6391): eaan5931.
[23] JIA B.Commentary: Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells[J]. Front Immunol, 2019, 10: 282.
[24] SINGH V, YEOH B S, CHASSAING B, et al.Dysregulated Microbial Fermentation of Soluble Fiber Induces Cholestatic Liver Cancer[J]. Cell, 2018, 175(3): 679-694.
[25] HOYLES L, FERNÁNDEZ-REAL J M, FEDERICI M, et al. Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women[J]. Nat Med, 2018, 24(7): 1070-1080.
[26] TEMRAZ S, NASSAR F, KREIDIEH F, et al.Hepatocellular Carcinoma Immunotherapy and the Potential Influence of Gut Microbiome[J]. Int J Mol Sci, 2021, 22(15): 7800.
[27] XU J, ZHAN Q, FAN Y, et al.Clinical Aspects of Gut Microbiota in Hepatocellular Carcinoma Management[J]. Pathogens, 2021, 10(7): 782.
[28] YOSHIMOTO S, LOO T M, ATARASHI K, et al.Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome[J]. Nature, 2013, 499(7456): 97-101.
[29] TIAN Y, GUI W, KOO I, et al.The microbiome modulating activity of bile acids[J]. Gut Microbes, 2020, 11(4): 979-996.
[30] MCGLONE E R, BLOOM S R.Bile acids and the metabolic syndrome[J]. Ann Clin Biochem, 2019, 56(3): 326-337.
[31] 刘丽娜, 张雪梅, 董蕾. 胆酸、小肠消化间期移行性复合波与胆固醇结石的关系[J]. 国外医学(消化系疾病分册), 2004, 24(5): 267-270.
[32] SCHUBERT K, OLDE DAMINK S W M, VON BERGEN M, et al. Interactions between bile salts, gut microbiota, and hepatic innate immunity[J]. Immunol Rev, 2017, 279(1): 23-35.
[33] SHAO J W, GE T T, CHEN S Z, et al.Role of bile acids in liver diseases mediated by the gut microbiome[J]. World J Gastroenterol, 2021, 27(22): 3010-3021.
[34] JIAO N, BAKER S S, CHAPA-RODRIGUEZ A, et al.Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD[J]. Gut, 2018, 67(10): 1881-1891.
[35] YANG Y, ZHANG J.Bile acid metabolism and circadian rhythms[J]. Am J Physiol Gastrointest Liver Physiol, 2020, 319(5): G549-G563.
[36] CHIANG J Y L, FERRELL J M. Bile Acid Metabolism in Liver Pathobiology[J]. Gene Expr, 2018, 18(2): 71-87.
[37] YAMADA S, TAKASHINA Y, WATANABE M, et al.Bile acid metabolism regulated by the gut microbiota promotes non-alcoholic steatohepatitis-associated hepatocellular carcinoma in mice[J]. Oncotarget, 2018, 9(11): 9925-9939.
[38] 周张杰, 蒋海燕, 钟薏, 等. 健脾固肠方通过提高短链脂肪酸产生菌的丰度减轻肠癌小鼠化疗后肠道炎症反应的机制探讨[J]. 中国中医基础医学杂志, 2020, 26(5): 618-621.
[39] LI M Y, LUO H J, WU X, et al.Anti-Inflammatory Effects of Huangqin Decoction on Dextran Sulfate Sodium-Induced Ulcerative Colitis in Mice Through Regulation of the Gut Microbiota and Suppression of the Ras-PI3K-Akt-HIF-1α and NF-κB Pathways[J]. Front Pharmacol, 2019, 10: 1552.
[40] 钟方为, 李庚喜, 曾立. 基于肠道菌群和短链脂肪酸代谢探讨绞股蓝总皂苷改善大鼠非酒精性脂肪肝的实验研究[J]. 中国中药杂志, 2021: 1-9.
[41] 胡炜, 刘洪斌, 王曼雪, 等. 清胰汤和姜黄素调整肠道微生态对重症急性胰腺炎的治疗机制[J]. 天津医药, 2018, 46(11): 1155-1160.
[42] 林小林, 唐林, 陈宝贵. 原发性肝癌的中医药治疗研究进展[J]. 江西中医药, 2021, 52(6): 77-80.
[43] 黄春兰, 刘华之. 参芪抑瘤方联合新辅助化疗对中晚期宫颈癌患者免疫功能及预后的影响[J]. 当代医学, 2021, 27(17): 139-140.
[44] 李瑞晓, 李琦, 季青. 肠道菌群对肿瘤免疫的影响及中医药干预研究[J]. 中华中医药杂志, 2020, 35(6): 2999-3002.
[45] CHEN X, CHEN X, GAO J, et al.AstragalosideⅢEnhances Anti-Tumor Response of NK Cells by Elevating NKG2D and IFN-γ[J]. Front Pharmacol, 2019, 10: 898.
[46] 孙晖, 张波, 钱海华, 等. 结直肠癌根治术后温针灸干预对患者免疫功能和肠道菌群的影响[J]. 针刺研究, 2021, 46(7): 592-597.
[47] LIU X, LI M, WANG X, et al.Effects of adjuvant traditional Chinese medicine therapy on long-term survival in patients with hepatocellular carcinoma[J]. Phytomedicine, 2019, 62: 152930.
[48] 冉云, 吕锦珍, 胡世平, 等. 中医正肝方治疗肝癌的疗效及对患者肝功能、肠道菌群和免疫功能的影响[J]. 海南医学, 2021, 32(14): 1821-1824.
[49] 戴玲, 倪颖, 姚欣, 等. 基于“补肾生髓成肝”的肝癌第三级预防方案的真实世界研究[J]. 中西医结合肝病杂志, 2019, 29(2): 118-120.
[50] 李素素, 濮文渊, 凌云, 等. 三物白散通过影响FXR表达逆转Th1/Th2漂移发挥抗肝癌免疫应答作用[J]. 中医学报, 2021, 36(5): 1021-1028.
[51] ZOU J, LI W, WANG G, et al.Hepatoprotective effects of Huangqi decoction (Astragali Radix and Glycyrrhizae Radix et Rhizoma) on cholestatic liver injury in mice: Involvement of alleviating intestinal microbiota dysbiosis[J]. J Ethnopharmacol, 2021, 267: 113544.
[52] HAN K, BOSE S, WANG J H, et al.In vivo therapeutic effect of combination treatment with metformin and Scutellaria baicalensis on maintaining bile acid homeostasis[J]. PLoS One, 2017, 12(9): e0182467.
[53] LI N, WANG B, WU Y, et al.Modification effects of SanWei GanJiang Powder on liver and intestinal damage through reversing bile acid homeostasis[J]. Biomed Pharmacother, 2019, 116: 109044.
[54] WANG T, HUANG S, WU C, et al.Intestinal Microbiota and Liver Diseases: Insights into Therapeutic Use of Traditional Chinese Medicine[J]. Evid Based Complement Alternat Med, 2021: 6682581.